Rovi expands its collaboration with Moderna. The Spanish pharmaceutical company announced on Monday, April 12th, that it is strengthening its collaboration for the manufacture of the active ingredient of Moderna’s Covid-19 vaccine. To this end, new industrial investment will be made at the Spanish group’s facilities in Granada.
This investment consists of the installation of a new line to support the production phases of the active ingredient of the mRNA vaccine, which are previous and additional to the formulation, filling, and finishing of the vaccine, as the company has informed the Spanish Securities and Exchange Commission (Cnmv). This line would have a production capacity equivalent to more than 100 million doses per year and is expected to start supplying markets outside the United States in the third quarter of 2021.
With this action, Rovi expands the activities it carries out in the manufacturing process of the Moderna vaccine: it will participate in the manufacture of the active ingredient as well as in its formulation, bottling and final packaging, prior to its distribution for administration to patients.
Read more about the agreement between Rovi and Moderna and find the most important business news of the day with our companion app, Born2Invest.
Rovi will carry out a new industrial investment in the facilities that the Spanish group has in Granada
“We are very happy about the collaboration with Moderna, whose vaccine against Covid-19 is one of the best positioned in the race to solve this health crisis; We are very excited that Rovi will go a step further and participate in the manufacture of the vaccine’s active ingredient, as further integration in the production process would allow us to support Moderna in its large-scale supply more broadly,” said Rovi’s CEO, Juan López-Belmonte.
Rovi is a pan-European specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and commercialization of small molecules and specialty biologics. The company has subsidiaries in Portugal, Germany, United Kingdom, Italy, France and Poland, and has a diversified portfolio of more than forty marketed products, including its reference product, Bemiparin, which is already marketed in 58 countries around the world.
Rovi posted a net profit of $72.7 million (€61.1 million) in 2020, 55% higher than in 2019, when it earned $46.7 million (€39.3 million). Rovi’s operating income increased by 10% in 2020 compared to the previous year, to $500 million (€420 million).
These results are due, according to the group, to the strength of the third-party manufacturing business, which grew by 39% in sales following the agreement for Moderna’s Covid-19 vaccine, as well as the specialty pharmaceuticals business, whose turnover increased by 4%.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
REE Reflects on ESG Recovery at its 2021 Sustainability Workshops
The Red Electrica Group is initiating a new line of action in four major critical areas. The first is the...
Nigeria Launches eNaira After One-Month Delay
CBDCs work just like the money people see in their bank accounts. The central bank will have complete control over...
DIAFASUD: An Initiative of the Burkinabe Diaspora in the US to Contribute to Africa’s Development
The Diaspora for the Sustainable Development of Africa (DIAFASUD) is the new NGO that was officially presented to the Burkinabe...
How Speculative Profit-Taking is Affecting the Prices of Vegetable Oils Futures
World vegetable oils prices were higher last week, but the markets came off the highs late in the week on...
Extremadura Subsidizes R&D&I Projects for Covid-19 Containment with €3 million
As a whole, with the resolution of the two calls that have been approved for the sanitary containment of the...
Cannabis2 weeks ago
ArgenCann Will Be Part of Expo Cannabis 2021
Crypto2 weeks ago
Filecoin Price Forecast: FIL Could Soon Increase by 18%
Featured2 weeks ago
Rice Demand Was Improved Last Week Over the Previous Week
Business2 weeks ago
Augmented Reality Investment Is Heating Up: Magic Leap, XRApplied